A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-cell malignancies Meeting Abstract
| Authors: | Mazza, I. A.; Barba, P.; Yuda, J.; Palomba, M. L.; Alderuccio, J. P.; De Vriendt, C.; Corradini, P.; Lim, F. L. W. I.; Zinzani, P. L.; Jain, N.; Leonard, J. T.; Coulson, M.; Hassounah, N.; Yang, X.; Lu, H.; Lewandowski, A.; Polli, J. R.; Klopfenstein, M.; Pastore, A.; Brisou, G. |
| Abstract Title: | A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-cell malignancies |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3099 |
| Language: | English |
| ACCESSION: | WOS:001159740302208 |
| DOI: | 10.1182/blood-2023-179061 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
